Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Moodys
McKinsey
Dow
Harvard Business School
Mallinckrodt

Last Updated: December 12, 2019

DrugPatentWatch Database Preview

Patent: 10,047,163

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Summary for Patent: 10,047,163
Title:Multispecific constructs
Abstract: Provided are novel multispecific antibody constructs and multispecific antibody drug conjugates (ADCs), and methods of using such antibodies and ADCs to treat cancer. IgG-like bispecific antibodies have different binding specificities on each arm of the antibody. They are similar in structure to monospecific IgGs in that they contain two heavy chains with VH, CH1, CH2 and CH3 regions, and two light chains with VL and CL regions.
Inventor(s): Liu; David (San Francisco, CA)
Assignee: AbbVie Stemcentrx LLC (North Chicago, IL)
Application Number:14/765,861
Patent Claims:see list of patent claims

Details for Patent 10,047,163

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech Inc HERCEPTIN HYLECTA trastuzumab; hyaluronidase-oysk INJECTABLE;SUBCUTANEOUS 761106 001 2019-02-28   Start Trial AbbVie Stemcentrx LLC (North Chicago, IL) 2033-02-08 RX search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 002 2017-06-22   Start Trial AbbVie Stemcentrx LLC (North Chicago, IL) 2033-02-08 RX Orphan search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 001 2017-06-22   Start Trial AbbVie Stemcentrx LLC (North Chicago, IL) 2033-02-08 RX Orphan search
Eli Lilly And Co LARTRUVO olaratumab INJECTABLE; INJECTION 761038 001 2019-07-10   Start Trial AbbVie Stemcentrx LLC (North Chicago, IL) 2033-02-08 RX Orphan search
Janssen Biotech DARZALEX daratumumab INJECTABLE;INJECTION 761036 002 2015-11-16   Start Trial AbbVie Stemcentrx LLC (North Chicago, IL) 2033-02-08 RX Orphan search
Janssen Biotech DARZALEX daratumumab INJECTABLE;INJECTION 761036 001 2015-11-16   Start Trial AbbVie Stemcentrx LLC (North Chicago, IL) 2033-02-08 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Medtronic
McKinsey
Merck
Johnson and Johnson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.